TXMD TherapeuticsMD, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 25743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY33.9%
TTM net income YoY-59.6%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR24.3%
Net income 3-yr CAGR-87.9%
Margins
Gross margin—
Operating margin-95.3%
Net margin3.3%
FCF margin—
EBITDA margin-85.1%
Returns
ROE0.4%
ROA0.3%
ROIC (approx.)-19.0%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets27.2%
Debt / equity0.00x
Current ratio3.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income27.59x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $3.02M | $1.76M | $1.30M | $69.96M | $2.57M |
| Cost of revenue | — | — | — | $1.40M | $1.40M |
| Gross profit | — | — | $1.30M | $68.57M | $1.17M |
| R&D expense | — | — | — | — | $7.09M |
| SG&A expense | $6.85M | $6.10M | $8.90M | $56.71M | $80.75M |
| Operating income | -$4.39M | -$6.11M | -$8.52M | $1.19M | -$79.58M |
| Interest expense | $8,000 | $10,000 | $166,600 | $200,000 | $32.92M |
| Pretax income | -$653,000 | -$2.34M | -$7.74M | $1.07M | -$79.31M |
| Income tax | — | -$31,000 | -$43,000 | — | — |
| Net income | -$569,000 | -$2.18M | -$10.28M | $112.00M | -$172.41M |
| EBITDA | -$4.01M | -$5.60M | -$7.60M | $2.38M | -$78.84M |
| EPS (basic) | -0.05 | -0.19 | -0.99 | 12.41 | -21.66 |
| EPS (diluted) | -0.05 | -0.19 | -0.99 | 11.96 | -21.66 |
| Weighted avg. shares (diluted) | 11.57M | 11.53M | 10,441 | 9.37M | 7.96M |
| Balance sheet | |||||
| Cash & equivalents | $7.48M | $5.06M | $4.33M | $49.32M | $64.91M |
| Receivables | — | — | — | — | $36.18M |
| Inventory | — | — | — | — | $7.62M |
| Current assets | $14.45M | $12.26M | $11.80M | $55.35M | $119.47M |
| PP&E, net | — | — | — | $78,000 | $823,000 |
| Intangibles | $3.76M | $4.32M | $6.10M | $6.94M | $7.14M |
| Total assets | $37.66M | $38.82M | $43.31M | $90.46M | $169.47M |
| Current liabilities | $4.79M | $5.17M | $6.85M | $46.84M | $252.89M |
| Short-term debt | — | — | — | — | $188.27M |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $188.27M |
| Total liabilities | $10.78M | $11.45M | $14.02M | $55.31M | $263.09M |
| Shareholders' equity | $26.88M | $27.37M | $29.29M | $35.14M | -$93.62M |
| Net debt | — | — | — | — | $123.36M |
| Shares outstanding | 11.57M | 11.53M | 11.53M | 9.50M | 8.60M |
| Cash flow statement | |||||
| Operating cash flow | $2.45M | $1.17M | -$23.08M | $9.36M | -$55.13M |
| Capital expenditure | — | — | — | — | $34,000 |
| Free cash flow | — | — | — | — | -$55.17M |
| Investing cash flow | — | — | — | -$355,000 | -$2.22M |
| Financing cash flow | — | — | $3.15M | -$235.21M | $129.55M |
| Depreciation & amortization | $384,000 | $509,000 | $922,000 | $1.19M | $736,000 |
| Stock-based compensation | $75,000 | $264,000 | $1.27M | $11.57M | $18.12M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.